TYME Technologies appoints Richie Cunningham as CEO alongside Steve Hoffman remaining Board Chairman and CSO

– USA, NJ –  Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies, today announced the appointment of Richie Cunningham, former Icagen CEO, and Boehringer Ingelheim executive as CEO, effective November 24, 2020, succeeding Steve Hoffman who will remain Board Chairman and CSO, after a successful tenure as CEO since 2015.

“We are fortunate to have been able to identify and bring on an individual with Mr. Cunningham’s significant experience in key facets sought by emerging biotech companies. His leadership and expertise in the biopharmaceutical industry, as well as his knowledge of efficient partnering strategies will be invaluable in helping TYME establish itself as a commercial organization with a pipeline of next-generation metabolic-based compounds,” said Board Chairman and Chief Science Officer, Steve Hoffman.

About Richie Cunningham

Mr. Cunningham brings more than 20 years of successful leadership experience spanning from pre-IND drug discovery through the commercialization and launch of over a dozen therapies in oncology, rare disease, infectious disease, respiratory, neurology, cardiovascular, and metabolic diseases. Richie brings to TYME an in-depth understanding of maximizing therapeutic lifecycles, enhancing efficiencies and outcomes in biotech business models, and most importantly a commitment to a values-driven culture.

Mr. Cunningham also brings significant experience in mergers & acquisitions, business development, strategy development, therapeutic launches, contracting, managed care, and sales & marketing. Most recently, Richie served as CEO at Icagen, leading the company through two transformational acquisitions, acquiring assets and talent out of Pfizer and Sanofi. While CEO at Icagen, he successfully negotiated and signed multiple licensing deals with Roche, Sanofi, and the Cystic Fibrosis Foundation.

Before joining Icagen, Mr. Cunningham was an executive with one of the world’s largest pharmaceutical companies, Boehringer Ingelheim, where he held a variety of key strategic and operational roles, including the launch of Boehringer’s first entrance into the oncology market with Gilotrif, an oral tyrosine kinase inhibitor, as a treatment for patients with non-small cell lung cancer.

Also, Mr. Cunningham excelled in the National Football League holding All-Pro honors for the Dallas Cowboys. His career in the NFL spanned from 1994 until his retirement in 2002.

“TYME is positioned for success and I look forward to working with the leadership team and TYME employees to achieve its strategic short- and long-term objectives. I am excited about the prospects of making a positive impact in the lives of patients and enhancing the value for all stakeholders,” said Richie Cunningham.

About Tyme Technologies

Tyme Technologies, Inc., is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system. With the development of TYME-18 and TYME-19, the Company believes that it is also emerging as a leader in the development of bile acids as potential therapies for cancer and COVID-19.

For more information: https://tymeinc.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.